Eltrombopag Powder, For Suspension
NDC 31722-301
Product Information
Eltrombopag (eltrombopag olamine) is a ANDA-approved product labeled by Camber Pharmaceuticals, Inc.. This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It is supplied as a powder, for suspension for oral administration. This product entry covers the primary NDC 31722-301 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 31722-301?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ELTROMBOPAG OLAMINE (UNII: 4U07F515LG)
- ELTROMBOPAG (UNII: S56D65XJ9G) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MANNITOL (UNII: 3OWL53L36A)
- SUCRALOSE (UNII: 96K6UQ3ZD4)
- XANTHAN GUM (UNII: TTV12P4NEE)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1859498 - eltrombopag 25 MG Powder for Oral Suspension
- RxCUI: 1859498 - eltrombopag (as eltrombopag olamine) 25 MG Powder for Oral Suspension
- RxCUI: 2058980 - eltrombopag 12.5 MG Powder for Oral Suspension
Which are the Pharmacologic Classes of this product?
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Increased Megakaryocyte Maturation - [PE] (Physiologic Effect)
- Increased Platelet Production - [PE] (Physiologic Effect)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- Thrombopoietin Receptor Agonist - [EPC] (Established Pharmacologic Class)
- Thrombopoietin Receptor Agonists - [MoA] (Mechanism of Action)
- UGT1A1 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A3 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A4 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A6 Inhibitors - [MoA] (Mechanism of Action)
- UGT1A9 Inhibitors - [MoA] (Mechanism of Action)
- UGT2B15 Inhibitors - [MoA] (Mechanism of Action)
- UGT2B7 Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.